Hello, everyone, and welcome to the middle of the week. This benchmark, as you know, means we are in the thick of a growing crop of meetings, deadlines and assorted things to get done by yesterday. So please join us as we reach for that mandatory cup of stimulation - we are nearly done with Pumpkin Spice - and tackle the to-do list. As always, we have gathered a few items of interest to help you get started. Hope your day goes well and you conquer the world. Stay in touch...
Deaths Are More Common On Digoxin Heart Drug: Study (Reuters)
China To Release Guidelines For Biosimilars (Financial Times)
European Crisis Spurs Pharma To Delay Treatments (Bloomberg News)
Abbott Labs Set To Consolidate India Operations (Economic Times)
Sanofi Signs $900M Allergy Pact With Selecta (Pharma Times)
USP Delays New Elemental Impurities Standards (InPharma Technologist)
India Rejects AstraZeneca Patent Plea On Cancer Drug (Reuters)
Glaxo To Cut 90 Jobs In Australia (Pharmacy News)
Medication Adherence Is Improved By Automatic Reminders (MedNews Today)
Forest Labs Submits Antipsychotic To FDA For Review (Associated Press)
Acadia Releases Promising Data On Parkinson's Psychosis Drug (Pharma Times)
Belarus Steps Up Efforts To Attract Foreign Pharma Investment (BTA)
Teva Won't Sell Gilead Generics Until June Or Court Ruling (Bloomberg News)
EDITOR'S NOTE: Please check this post for updates
1 Comment
Please don't, Forest Labs.